Current Partners

Baxalta, Inc. now part of Shire 

Development and License Agreement

Global strategic immuno-oncology collaboration for development of novel therapeutics against up to six checkpoint targets. On a product-by-product basis, following successful completion of Phase 1 clinical trials, Baxalta will have exclusive option rights to complete late-stage development and worldwide commercialization. Symphogen will receive an upfront payment of $175 million (€160 million) from Baxalta in exchange for the exclusive option rights for six checkpoint therapies. Symphogen will be responsible for performing R&D through Phase 1 clinical trials at its own expense. The agreement holds a total potential value up to €1.4 billion ($1.6 billion) in option fees and milestones over the long-term, in addition to royalties on worldwide sales.

 

 

 

Genentech, Inc. 


Development and License Agreement

Global strategic collaboration for development of antibody therapeutics against up to three undisclosed infectious disease targets. Symphogen has applied its proprietary Symplex™ antibody discovery technology platform to identify novel infectious disease drug candidates. In parallel, Genentech made an undisclosed upfront payment to Symphogen, as well as an equity investment in Symphogen. In addition, Symphogen is eligible to receive milestone payments upon the success of certain research and development milestones, as well as royalties on any products developed and commercialized by Genentech as a result of this collaboration. The total value of the agreement has the potential to exceed $ 330 million.